40 results about "Monoamine Oxidase Type B" patented technology
Filter
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Monoamine oxidase B, also known as MAOB, is an enzyme that in humans is encoded by the MAOB gene. The protein encoded by this gene belongs to the flavin monoamine oxidase family. It is an enzyme located in the outer mitochondrial membrane.
The invention discloses a preparation method and application of a two-photon ratio type fluorescent probe in precisely detecting monoamine oxidase B in tumor cells. The probe consists of a two-photonnaphthalene derivative biological framework based on fluorescenceresonanceenergy transfer, and p-methylaminophenol fluorophore which are connected together, and a propylamine unit which is introduced for specific recognition of monoamine oxidase B. Corresponding imine ions are generated through an enzymatic oxidation deamination reaction, are further hydrolyzed and eliminated, then dye hydroxylis released for another time, and the ratio of fluorescence emission signals can be changed. The advantages are that the distance of fluorescent spectrums of energy donors and acceptors is enlarged, interference of spectrums is reduced, the sensitivity is high, and interference of various environment conditions upon analysis is effectively avoided. A potential tool is provided for clinical detection on significant marker enzymes of Alzheimer's disease in living bodies.
The invention discloses coumarin / pyridone heterozygous derivatives represented by a formula (I) shown in the description or a pharmaceutically-acceptable salt of the derivatives. The preparation method of the coumarin / pyridone heterozygous derivatives comprises the following steps: one pyridone derivative represented by a formula 3 shown in the description is obtained by a series of synthesis by using one hydroxypyrone with different substituent groups represented by a formula 1 shown in the description as a raw material; and a compound represented by a formula 4 shown in the description is subjected to a condensation reaction to obtain a compound represented by a formula 5 shown in the description, one-step bromination is performed to obtain a compound represented by a formula 6 shown inthe description, the compound represented by the formula 6 and the pyridone derivative represented by the formula 3 are subjected to a one-step nucleophilic substitution reaction to obtain a compoundrepresented by a formula 7 shown in the description, and finally an alkylprotecting group in a pyridone structure is removed to obtain one target compound represented by the formula (I). The compounds provided by the invention are a novel series of single-molecular multi-target series drugs, and have iron chelation, targeted MAO-B inhibitory activity, antioxidant activity, unique advantages for an Alzheimer disease with complicated pathogenesis, a clear mechanism of action and excellent activity.
The invention belongs to the field of medicine and chemical industry, and specifically discloses a 4-flexible amine-2-aryl vinyl quinoline derivative and a preparation method thereof, and applications of the 4-flexible amine-2-aryl vinyl quinoline derivative in preparation of anti-Alzheimer disease drugs, wherein the chemical formula of the 4-flexible amine-2-aryl vinyl quinoline derivative is defined in the specification. The invention further discloses the preparation method and the uses of the 4-flexible amine-2-aryl vinyl quinoline derivative. According to the present invention, the 4-flexible amine-2-aryl vinyl quinoline derivative has advantages of monoamine oxidase-B activity inhibiting, A[beta] aggregation resistance, anti-oxidation activity, metal complexing, low biological toxicity and good safety, such that the 4-flexible amine-2-aryl vinyl quinoline derivative has broad application space in the preparation of anti-Alzheimer disease drugs.
The present invention provides an ex vivo method for aiding the diagnosis of Alzheimer's disease in a patient, the method comprising the steps of determining the level of expression of at least four platelet proteins in a platelet sample from the patient selected from monoamine oxidase-B, coagulation factor Xllla, total tropomyosin (a and 13), WD-repeat protein 1 and apolipoprotein E4; and comparing the result of (i) to a control value, wherein a result higher than the control value is indicative of Alzheimer's disease. Preferably, the method of the invention further comprises determining the level of expression of wild-type GSTO-1 or mutant GSTO-1.